An interventional study of Group I:Extended Totally Extraperitoneal Retro-muscular Repair in Outcomes, Extraperitoneal and Ventral Hernia, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
The aim of this study is to assess the short-term outcomes of endoscopic extended totally extraperitoneal repair in primary small-sized ventral hernias, with specific regard to surgical site occurrences and hernia recurrence.
Ventral hernia repair is one of the most common surgical procedures in general surgical practice, yet the optimal treatment for ventral hernias remains debatable. Open surgical methods were the sole available techniques for ventral hernia repair until 1993.
Although the exact incidence of recurrence is unknown, it is estimated that 30-50% of patients developed recurrent hernias following primary suture repair, which decreased significantly to 1-14% with the introduction of prosthetic meshes.
Laparoscopic ventral hernia repair was first introduced in 1993 by Le Blanc and Booth, who reported the initial case managed by intraperitoneal onlay mesh , demonstrating early recovery and reduced surgical wound complications. However, adhesive bowel obstruction, mesh erosion, and enterocutaneous fistula arising from direct contact of the mesh with the viscera remained notable disadvantages of intraperitoneal onlay mesh.
espite varying approaches, debate continues between open and minimally invasive techniques regarding the optimal placement of the mesh. Current evidence-based trends suggest four general principles have emerged in contemporary ventral hernia management: mesh reinforcement, retromuscular mesh placement, primary fascial closure, and minimally invasive techniques.
The aim of this study is to assess the short-term outcomes of endoscopic extended totally extraperitoneal repair in primary small-sized ventral hernias, with specific regard to surgical site occurrences and hernia recurrence.
230 studies on the registry are indexed under Hernia, Ventral; 45 are open to participants now.
This study's enrollment of 30 is below the median of 90 across 153 interventional studies indexed under Hernia, Ventral.
Browse Hernia, Ventral studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 patients diagnosed with uncomplicated ventral hernias who are admitted to the GIT and Laparoscopic Surgery Unit
Procedure: Group I:Extended Totally Extraperitoneal Retro-muscular Repair
30 patients diagnosed with uncomplicated ventral hernias who are admitted to the GIT and Laparoscopic Surgery
Incidence of Morbidity (Surgical Field Occurrence/Surgical Site Occurrence)
Time frame: scheduled at 1 week, 1 month, 3 months, 6 months, and 12 months.
Hernia recurrence
Time frame: scheduled at 1 week, 1 month, 3 months, 6 months, and 12 months.
Plan to share: Yes — It will be available if it needed
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Jul 2025, 11 months.
Of 75 non-industry interventional studies with no phase under Hernia, Ventral, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 11 months is below that.
Counting every sponsor, half of 88 studies reached it within 37 months; a quarter within 19 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.